Pear Tree Pharmaceuticals, Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Pear Tree Pharmaceuticals, Inc.
'Breakthrough' status granted to Aimmune's peanut allergy drug
The FDA has granted breakthrough therapy designation (BTD) to Aimmune Therapeutics' investigational oral immunotherapy for peanut allergy, known as AR101.
21st Century Cures leaders vow to work out differences
The two members of the House who have been leading an effort to overhaul certain functions at the FDA and the National Institutes of Health and other areas of the US biomedical research and development enterprise wit the goal of accelerating the discovery, development and delivery of medical therapies have vowed to work out their differences and move the legislative process forward.
ZMapp, 'modern techniques' too late to save doctor
The death of a doctor who was being treated for Ebola in the US with the best of what medical care has to offer, including the hard-to-obtain experimental drug ZMapp, was a stark reminder that in the very advanced stages, even the most modern techniques are not enough to save a patient's life when they reach a critical threshold, said Dr Jeff Gold, chancellor of the University of Nebraska Medical Center (UNMC) in Omaha.
US Capitol Capsule: Another US healthcare crisis: VA woes go beyond wait times
It's been a rough year for healthcare under the Obama administration – first with the botched launch of the Affordable Care Act insurance exchanges, and now with a scandal involving falsified records of patient wait times at medical facilities operated by the Veterans Health Administration (VHA), which is likely to linger throughout the time the president has left at the White House.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice